Zenflow raises $31m in Series A
Fink Densford | February 7, 2018
Urology medical device maker Zenflow said today it closed a $31.4 million Series A round of financing to support the development of minimally invasive devices designed to treat obstructive urinary symptoms related to benign prostatic hyperplasia.
The round was led by Invus Opportunities, F-Prime Capital Partners and Medical Technology Venture Partners and was joined by other new and existing investors, the San Francisco-based company said.
Zenflow said it has also received grant funding from the National Institutes of Health and the National Science Foundation.
The company’s first product is the Spring System device, which is designed to deliver a low-profile superelastic implant into the prostatic urethra. The system is intended to allow for a simple, physician-led procedure to relieve BPH symptoms with a fast recovery time and minimal side effects.
